Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2019 16:05 ET | Source: Scholar Rock

Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy

Dosing of patients has commenced in TOPAZ, the Phase 2 clinical trial of SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA)Preliminary PK/PD data from a subset of patients are anticipated by...
April 30, 2019 16:05 ET | Source: Scholar Rock

Scholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors

CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
April 11, 2019 07:00 ET | Source: Scholar Rock

Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources

CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
April 02, 2019 13:00 ET | Source: Scholar Rock

Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy

Preclinical data presented at the American Association for Cancer Research annual meeting provide further support for the potential of SRK-181 to overcome primary resistance to checkpoint blockade...
March 18, 2019 17:31 ET | Source: Scholar Rock

Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress

Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage CompanyPresented Compelling Preclinical Data from the SRK-181 Cancer Immunotherapy...
March 12, 2019 16:30 ET | Source: Scholar Rock

Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance

Selective inhibition of TGFβ1 activation enables immune cell entry into the tumor microenvironment in preclinical models, demonstrating potential for overcoming a key mechanism of primary resistance...
March 06, 2019 07:00 ET | Source: Scholar Rock

Scholar Rock to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in...
February 26, 2019 07:00 ET | Source: Scholar Rock

Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans

Favorable Safety Profile Across All Tested Doses Supports Initiation of a Phase 2 Trial in Patients with Spinal Muscular Atrophy (SMA)Pharmacodynamic Results Demonstrate Robust and Sustained Target...
January 03, 2019 08:00 ET | Source: Scholar Rock

Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
December 03, 2018 16:05 ET | Source: Scholar Rock

Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy

CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...